Transitional Cell Carcinoma in Dogs: Bladder Cancer Signs and Management
Transitional cell carcinoma, sometimes referred to as urothelial carcinoma, is the most common urinary tract cancer in dogs. It arises from the transitional epithelium that lines the bladder — the specialised cells that allow the bladder to expand and contract — and most frequently develops at the trigone, the triangular region at the base of the bladder where the ureters enter and the urethra exits. This anatomical location makes it particularly challenging to manage surgically and is central to understanding why this cancer behaves the way it does.
Which Dogs Are Most Commonly Affected
Certain breeds are significantly over-represented in transitional cell carcinoma cases. Scottish Terriers have been shown in multiple studies to have a risk approximately 18 to 20 times higher than other dog breeds. West Highland White Terriers, Beagles, Shetland Sheepdogs, and Wire Fox Terriers also appear at elevated rates. Female dogs are affected approximately twice as often as males, which mirrors the higher incidence of urinary tract transitional cell carcinoma in women compared to men in human medicine.
Middle-aged to older dogs are most commonly diagnosed, with a typical age range of nine to eleven years. Obesity has been identified as a risk factor in some studies, and prior exposure to certain insecticides — particularly older flea control products containing organophosphates or carbamates — has been associated with increased risk, though owners should not over-interpret this, as the relationship is complex.
Clinical Signs and Why They Are Easily Missed
The symptoms of transitional cell carcinoma closely mimic those of urinary tract infection, which is one of the reasons the diagnosis is so frequently delayed. Dogs present with increased frequency of urination, straining, visible discomfort when urinating, blood in the urine, and accidents in the house despite appearing to want to go outside. These signs are often initially — and reasonably — treated as a straightforward bacterial cystitis.
The critical red flag is when a dog fails to respond appropriately to antibiotic treatment, or when urinary signs recur persistently. Any dog — particularly a Scottish Terrier or other predisposed breed — that has recurrent or refractory urinary symptoms should be investigated further rather than simply receiving repeated courses of antibiotics. It is also worth noting that urinary tract infections are common secondary complications of transitional cell carcinoma, so a positive urine culture does not rule out an underlying tumour.
How Transitional Cell Carcinoma Is Diagnosed
Urinalysis and urine cytology are initial steps and may reveal abnormal transitional cells in the urine, though sensitivity is variable. Abdominal ultrasound is the most practical and widely available imaging tool for identifying a bladder mass, and it can provide information about the size and location of the tumour, ureteral involvement, and regional lymph node status.
A veterinary bladder tumour antigen test (VBTA) using urine is available as a screening tool, though it has a relatively high false-positive rate and is best used in conjunction with imaging rather than as a standalone diagnostic. Cystoscopy — direct visualisation of the bladder interior using an endoscope — allows biopsy under direct vision and is considered the gold standard for obtaining diagnostic tissue, though it requires specialist equipment and general anaesthesia.
CT scanning provides superior detail for staging, particularly for evaluating urethral involvement, lymph node metastasis, and the relationship of the tumour to surrounding structures, and is increasingly used at veterinary referral centres.
The Challenge of Surgical Management
The trigone location of most transitional cell carcinomas in dogs means that complete surgical excision is rarely achievable. The ureters and urethra converge at this site, and removing sufficient tissue margins would compromise urinary function. Unlike bladder tumours in other positions, where partial cystectomy might offer meaningful debulking, trigone tumours generally cannot be adequately managed surgically alone.
For the small proportion of dogs with tumours located away from the trigone, partial cystectomy may be feasible, but local recurrence is common, and the procedure is most effective when combined with additional treatments. Urinary diversion procedures are occasionally employed for cases with complete urethral obstruction, but they are complex and associated with significant complication rates.
Medical Management: The Mainstay of Treatment
Because surgical cure is rarely achievable, medical management forms the backbone of treatment for most dogs with transitional cell carcinoma. The non-steroidal anti-inflammatory drug piroxicam has been studied extensively in canine transitional cell carcinoma and has demonstrated meaningful anti-tumour activity through both direct effects on tumour cells and indirect anti-angiogenic mechanisms. It achieves partial or complete remission in a proportion of dogs and disease stabilisation in many more, and it is well-tolerated in most patients when given with food and gastroprotectants.
Mitoxantrone in combination with piroxicam has shown response rates of approximately 35% in clinical trials, and this combination has been a standard of care protocol for many years. More recently, vinblastine combined with piroxicam has demonstrated comparable or superior results in some studies and represents a reasonable alternative.
Toceranib phosphate (Palladia) has shown activity against transitional cell carcinoma, particularly in combination with non-steroidal anti-inflammatory drugs, and is increasingly used in first-line and rescue settings. Carboplatin and other platinum-based drugs have also been evaluated with variable results.
Palliative Measures and Quality of Life
Managing urinary obstruction is an important aspect of palliative care for advanced disease. Urethral stenting — placement of a metal stent to keep the urethra open as tumour encroaches — can restore urinary flow and dramatically improve quality of life in dogs with partial or complete urethral obstruction. This is a specialist procedure but increasingly available at referral centres.
Urinary tract infections should be monitored and treated as they arise, as secondary infections are common and can significantly worsen quality of life if left unaddressed.
Prognosis and What to Expect
Transitional cell carcinoma in dogs is generally not curable with current treatments, and the focus of management is on extending good-quality life. Median survival times with medical management range from approximately 6 to 12 months depending on the protocol used, disease stage, and individual patient factors. Dogs that respond to treatment can enjoy extended periods of good quality of life, and the gradual nature of disease progression in many cases allows time for careful, considered decision-making about ongoing management and end-of-life planning.